Up-coming presentations by NMIN researchers:
NMIN Scientific Meeting
September 13-14, 2019 | Vancouver, BC
- Marcel Bally (NMIN Targeted Drug Delivery Theme Leader; University of British Columbia)
- Pieter Cullis (NMIN Scientific Director & CEO; University of British Columbia)
- Shana Kelley (NMIN Diagnostics Theme Leader; University of Toronto)
- Gilbert Walker (NMIN Associate Scientific Director; University of Toronto)
Advancing research, innovation and training in nanomedicines to maintain Canada as the world leader in the field.
The NanoMedicines Innovation Network (NMIN) is advancing “smart” medicines to cure disease by delivering small molecule drugs more specifically to disease sites and enabling the clinical use of gene therapies.
NMIN brings 60 Principal Investigators from 17 institutions across Canada together with 15 companies and 8 not-for-profit research and granting institutions in a network committed to expanding and improving Canada’s position as a global leader in nanomedicines R&D.
NMIN is funded by the Government of Canada through the Networks of Centres of Excellence (NCE) Program.
that enhance the therapeutic properties of small molecule drugs, and enable gene therapies.
Develop new diagnostics
that enable more precise disease detection and treatment, based on nanotechnology.
in the technology and business of nanomedicines, guided by market needs for HQP with skills required by the R&D community.
products and technologies, by implementing a cohesive IP and commercialization strategy.
2350 Health Sciences Mall, Room 5451 | University of British Columbia | Vancouver, BC V6T 1Z3 Canada